BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29253765)

  • 21. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
    Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
    Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition.
    Khan A; Valli E; Lam H; Scott DA; Murray J; Hanssen KM; Eden G; Gamble LD; Pandher R; Flemming CL; Allan S; Osterman AL; Haber M; Norris MD; Fletcher JI; Yu DMT
    Oncogene; 2020 Apr; 39(17):3555-3570. PubMed ID: 32123312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
    Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
    Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Lactate Metabolism by Inhibiting MCT1 or MCT4 Impairs Leukemic Cell Proliferation, Induces Two Different Related Death-Pathways and Increases Chemotherapeutic Sensitivity of Acute Myeloid Leukemia Cells.
    Saulle E; Spinello I; Quaranta MT; Pasquini L; Pelosi E; Iorio E; Castelli G; Chirico M; Pisanu ME; Ottone T; Voso MT; Testa U; Labbaye C
    Front Oncol; 2020; 10():621458. PubMed ID: 33614502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of co-inhibition of MCT1 gene and NHE1 gene on proliferation and growth of human lung adenocarcinoma cells].
    Zhang GZ; Huang GJ; Li WL; Wu GM; Qian GS
    Ai Zheng; 2002 Jul; 21(7):719-23. PubMed ID: 12479094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.
    Vijay N; Morse BL; Morris ME
    Pharm Res; 2015 Jun; 32(6):1894-906. PubMed ID: 25480120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
    Benjamin D; Robay D; Hindupur SK; Pohlmann J; Colombi M; El-Shemerly MY; Maira SM; Moroni C; Lane HA; Hall MN
    Cell Rep; 2018 Dec; 25(11):3047-3058.e4. PubMed ID: 30540938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure.
    Andersen S; Solstad Ø; Moi L; Donnem T; Eilertsen M; Nordby Y; Ness N; Richardsen E; Busund LT; Bremnes RM
    Urol Oncol; 2015 Aug; 33(8):338.e9-17. PubMed ID: 26066969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic disruption of lactate/H+ symporters (MCTs) and their subunit CD147/BASIGIN sensitizes glycolytic tumor cells to phenformin.
    Marchiq I; Le Floch R; Roux D; Simon MP; Pouyssegur J
    Cancer Res; 2015 Jan; 75(1):171-80. PubMed ID: 25403912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models.
    Schneiderhan W; Scheler M; Holzmann KH; Marx M; Gschwend JE; Bucholz M; Gress TM; Seufferlein T; Adler G; Oswald F
    Gut; 2009 Oct; 58(10):1391-8. PubMed ID: 19505879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MCT1, MCT4 and CD147 expression and 3-bromopyruvate toxicity in colorectal cancer cells are modulated by the extracellular conditions.
    Pereira-Vieira J; Azevedo-Silva J; Preto A; Casal M; Queirós O
    Biol Chem; 2019 May; 400(6):787-799. PubMed ID: 30699066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration.
    De Saedeleer CJ; Porporato PE; Copetti T; Pérez-Escuredo J; Payen VL; Brisson L; Feron O; Sonveaux P
    Oncogene; 2014 Jul; 33(31):4060-8. PubMed ID: 24166504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.
    Guan X; Morris ME
    AAPS J; 2020 Jun; 22(4):84. PubMed ID: 32529599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of Acetate Utilization by Monocarboxylate Transporter 1 (MCT1) in Hepatocellular Carcinoma (HCC).
    Jeon JY; Lee M; Whang SH; Kim JW; Cho A; Yun M
    Oncol Res; 2018 Jan; 26(1):71-81. PubMed ID: 28390113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Vivo Anticancer Activity of AZD3965: A Systematic Review.
    Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
    Beloueche-Babari M; Wantuch S; Casals Galobart T; Koniordou M; Parkes HG; Arunan V; Chung YL; Eykyn TR; Smith PD; Leach MO
    Cancer Res; 2017 Nov; 77(21):5913-5924. PubMed ID: 28923861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased densities of monocarboxylate transporter MCT1 after chronic hyperglycemia in rat brain.
    Canis M; Maurer MH; Kuschinsky W; Duembgen L; Duelli R
    Brain Res; 2009 Feb; 1257():32-9. PubMed ID: 19118535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Nonradioactive High-Throughput Screening-Compatible Cell-Based Assay to Identify Inhibitors of the Monocarboxylate Transporter Protein 1.
    Bailey TL; Nieto A; McDonald PH
    Assay Drug Dev Technol; 2019 Aug; 17(6):275-284. PubMed ID: 31532712
    [No Abstract]   [Full Text] [Related]  

  • 39. Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
    Gurrapu S; Jonnalagadda SK; Alam MA; Ronayne CT; Nelson GL; Solano LN; Lueth EA; Drewes LR; Mereddy VR
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3282-3286. PubMed ID: 27241692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional heterogeneity of MCT1 and MCT4 in metabolic reprogramming affects osteosarcoma growth and metastasis.
    Sheng G; Gao Y; Wu H; Liu Y; Yang Y
    J Orthop Surg Res; 2023 Feb; 18(1):131. PubMed ID: 36814318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.